At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 86 enrolled
Drug / intervention
V950 +2 morebiological
Likely dose
V950 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of V950 Formulated on Aluminum-Containing Adjuvant With or Without ISCOMATRIX™ in Patients With Alzheimer Disease
In Brief
A Phase 1 clinical trial evaluating V950, ISCOMATRIX™, and 1 other intervention for Alzheimer Disease. Completed, enrolled 86 participants.
Detailed Summary
The purpose of this study is to test the safety, tolerability and the immune response to an investigational vaccine, V950, with or without ISCOMATRIX™ (IMX).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedApr 2007
Primary CompletionJan 2012
TodayJul 2026
First PostedApr 23, 2007
Enrollment StartMar 1, 2007
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 19.2 years ago
Interventions
V950biological
V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.
ISCOMATRIX™biological
ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.
Placebo to V950biological